MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Income Overview
Net Income
-$25,246,000
Unit: Dollar
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Income Statement
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Licensing revenue
-
-
0*
0
Research and development
19,576,000
13,390,000
12,107,500*
12,826,000
General and administrative
7,403,000
6,909,000
5,407,000*
2,991,000
Total operating expenses
26,979,000
20,299,000
17,514,500*
15,817,000
Loss from operations
-26,979,000
-20,299,000
-17,514,500*
-15,817,000
Interest income
1,825,000
1,982,000
2,235,500*
1,558,000
Net loss
-25,154,000
-18,317,000
-15,279,000*
-14,259,000
Unrealized (gain) loss on marketable securities
-92,000
-439,000
-56,000*
66,000
Comprehensive loss
-25,246,000
-18,756,000
-15,335,000
-14,193,000
Basic EPS
-0.13
-0.1
-0.092
-0.08
Basic Average Shares
186,798,000
186,400,000
166,021,000
168,782,000
Page 1
Unit: Dollar. Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Income Statement
Comprehensive loss
-$25,246,000
(-27.10%↓ Y/Y)
Net loss
-$25,154,000
(-26.52%↓ Y/Y)
Unrealized (gain) loss on
marketable securities
-$92,000
(-611.11%↓ Y/Y)
Interest income
$1,825,000
(54.01%↑ Y/Y)
Loss from operations
-$26,979,000
(-28.07%↓ Y/Y)
Total operating
expenses
$26,979,000
(28.07%↑ Y/Y)
Research and development
$19,576,000
(19.26%↑ Y/Y)
General and
administrative
$7,403,000
(59.17%↑ Y/Y)
Buy us a coffee
Compass Therapeutics, Inc. (CMPX)
Compass Therapeutics, Inc. (CMPX)